Colchicine in atherosclerotic cardiovascular disease

In conclusion, while colchicine shows promise in reducing MACE, its net risk–benefit profile requires further elucidation before its widespread adoption into clinical practice for the secondary prevention of atherosclerotic cardiovascular disease. Much more large-scale, long-term trial data are still needed in this space.

http://heart.bmj.com/cgi/content/short/110/9/618?rss=1

Source: Heart - April 15, 2024 Category: Cardiology Authors: Tucker, B., Goonetilleke, N., Patel, S., Keech, A. Tags: Review articles Reviews Source Type: research